Drug intelligence / Profile preview

Cinchophen

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Cinchophen is an analgesic drug first synthesized in 1887 and introduced commercially in 1908 primarily for the treatment of gout and arthritis. It belongs to the class of phenylquinolines, organic compounds containing a quinoline moiety substituted with a phenyl group. The drug acts by reducing uric acid buildup, providing relief from gout symptoms and arthritis pain. However, its use in humans was largely discontinued by the 1930s due to serious hepatotoxicity including liver damage, jaundice, hepatitis, and fatal outcomes. Despite this, it remains used in veterinary medicine combined with prednisolone for treating arthritis in animals. It can be administered orally or intravenously. Chemically it is known as 2-phenylquinoline-4-carboxylic acid with formula C16H11NO2 and molar mass approximately 249 g/mol.

Brand names
AtophanQuinophanPhenaquin
Other names
phenylcinchoninic acidartamagotanalutylatigoaatocinatofantopholvantylRHEUMINartamin
02

Targets

OAT4 (Solute carrier family 22 member 11)

Beyond the preview

Go deeper on Cinchophen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cinchophen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call